Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.

被引：0
|
作者：
Zhou, Qing
Yang, Nong
Zhao, Jun
Dong, Xiaorong
Wang, Huijuan
Yuan, Ying
Yu, Yan
Zhang, Meijiang
Zhang, Sujie
Huang, Mengna
Shen, Yuping
Wu, Yi-Long
机构：
[1] Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[2] Hunan Canc Hosp, Changsha, Peoples R China
[3] Beijing Canc Hosp, Beijing, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongi Med Coll, Wuhan, Peoples R China
[5] Henan Canc Hosp, Zhengzhou, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Hangzhou, Zhejiang, Peoples R China
[7] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[8] Innovent Biol Inc, Suzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3110
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study
    Zhou, Qing
    Yang, Nong
    Zhao, Jun
    Zhao, Mingfang
    Yu, Yan
    Yuan, Ying
    Wang, Huijuan
    Li, Xingya
    Dong, Xiaorong
    Sun, Longhua
    Zhang, Tongmei
    Huang, Dingzhi
    Chu, Qian
    Huang, Jingjing
    Zhang, Sujie
    Huang, Mengna
    Shen, Yuping
    Wu, Yi-Long
    CANCER RESEARCH, 2023, 83 (08)
  • [2] Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study
    Zhou, Q.
    Meng, X.
    Sun, L.
    Huang, D.
    Yang, N.
    Yu, Y.
    Zhao, M.
    Zhuang, W.
    Hu, Y.
    Pan, Y.
    Sun, M.
    Shan, J.
    Guo, R-H.
    Chu, Q.
    Xu, C.
    Lin, J.
    Huang, J.
    Huang, M.
    Shen, Y.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1662 - S1662
  • [3] A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
    Kristeleit, Rebecca Sophie
    Shapiro, Geoffrey
    LoRusso, Patricia
    Infante, Jeffrey R.
    Flynn, Michael
    Patel, Manish R.
    Tolaney, Sara M.
    Hilton, John Frederick
    Calvert, Alan Hilary
    Giordano, Heidi
    Isaacson, Jeffrey D.
    Borrow, Jennifer
    Allen, Andrew R.
    Jaw-Tsai, Sarah S.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Phase I dose-escalation study of pasireotide LAR in patients with advanced neuroendocrine tumors.
    Phan, Alexandria T.
    Wolin, Edward M.
    Chan, Jennifer A.
    Huang, Jerry M.
    Hudson, Michelle
    Hughes, Gareth
    Shen, Guoxiang
    Strosberg, Jonathan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
    Yuan, Y.
    Deng, Y.
    Jin, Y.
    Pan, Y.
    Wang, C.
    Wang, Z.
    Zhang, Z.
    Meng, X.
    Hu, Y.
    Zhao, M.
    Wang, H.
    Yang, N.
    Wu, D.
    Dong, X.
    Huang, D.
    Sun, M.
    Liu, L.
    Hua, D.
    Guo, Z.
    Ding, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1512 - S1512
  • [6] A phase I dose-escalation study of IMGN388 in patients with solid tumors.
    Thompson, D. S.
    Patnaik, A.
    Bendell, J. C.
    Papadopoulos, K.
    Infante, J. R.
    Mastico, R. A.
    Johnson, D.
    Qin, A.
    O'Leary, J. J.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Preliminary results from a pooled analysis of two phase I studies.
    Yuan, Ying
    Deng, Yanhong
    Jin, Yongdong
    Pan, Yueyin
    Wang, Cunji
    Wang, Zhiwu
    Zhang, Zhiye
    Meng, Xiangjiao
    Hu, Yi
    Zhao, Mingfang
    Wang, Huijuan
    Yang, Nong
    Wu, Dongde
    Dong, Xiaorong
    Huang, Dingzhi
    Sun, Meili
    Liu, Lian
    Hua, Dong
    Guo, Zengqing
    Ding, Ke-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.
    Berlin, Jordan
    Ramanathan, Ramesh K.
    Strickler, John H.
    Subramaniam, Deeps Suresh
    Hurwitz, Herbert
    Kang, Yoon-Koo
    Kim, Tae-You
    Shepherd, Stacie Peacock
    Xiong, Hao
    Hetman, Robert
    Nickner, Caroline
    Dudley, Matthew W.
    Giranda, Vincent L.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
    Cao, Junning
    Ji, Dongmei
    Chen, Zhiyu
    Shen, Weina
    Wang, Jin
    Li, Baoyue
    Chi, Haidong
    Long, Amanda
    Gao, Ling
    Li, Jin
    ONCOLOGIST, 2017, 22 (06): : 638 - +
  • [10] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
    Demetri, George D.
    Lo Russo, Patricia
    MacPherson, Lain R. J.
    Wang, Ding
    Morgan, Jeffrey A.
    Brunton, Valerie G.
    Paliwal, Prashni
    Agrawal, Shruti
    Voi, Maurizio
    Evan, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6232 - 6240
12345